Yvonne de Jong

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation

Elisabeth F.P. Peterse, Bertine Niessen, Ruben D. Addie et al. · British Journal of Cancer · 2018 · 61 citations · Full text

Medicine, Oncology, Pharmacology +10

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma

Yvonne de Jong, David Monderer, Emeline Brandinelli et al. · Oncogenesis · 2018 · 57 citations · Full text

Medicine, Oncology, Pharmacology +12

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes

Yvonne de Jong, Martha Ingola, Inge H. Briaire‐de Bruijn et al. · Clinical Sarcoma Research · 2019 · 47 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin

Zuzanna Baranski, Yvonne de Jong, Trayana Ilkova et al. · Oncotarget · 2015 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma

Elisabeth F.P. Peterse, Brendy E.W.M. van den Akker, Bertine Niessen et al. · Molecular Cancer Research · 2017 · 42 citations · Full text

Medicine, Molecular Biology, Oncology +15